Clinical trial Recruiting at 1 site Interventional Ages 18 to 64 Women only

Imaging endometriosis with a special PET tracer in adult women

Official title: Prospective Trial of [18F]AlF-FAPI-74 for PET Imaging of Fibroblast Activation Protein in Patients With Endometriosis

Run by Universitaire Ziekenhuizen KU Leuven · NCT07876648 · Data updated 2026-11-12

This study tests whether a PET/CT scan using [18F]AlF-FAPI-74 can help detect endometriosis lesions in women who are planning laparoscopy.

Quick facts

Study typeInterventional
Ages18 Years to 64 Years
SexWomen only
Enrollment64 (estimated)
SponsorUniversitaire Ziekenhuizen KU Leuven
Academic / other
Drugs / interventionsradiation
Locations1 site (Leuven)
StatusRecruiting
StartedSeptember 30, 2026
Main results expectedAugust 31, 2029
Study endsAugust 31, 2029
Registry record updatedOctober 19, 2026
Trial IDNCT07876648 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adult women (18+) with suspected deep infiltrating or superficial peritoneal endometriosis who are scheduled for laparoscopy.

Probably not a fit

Patients whose lesions are not detected by PET/CT or who do not have lesions adjacent to surgical targets may not see a direct benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective imaging study evaluates the use of [18F]AlF-FAPI-74 PET/CT to detect endometriosis before laparoscopic surgery in adult women. Participants receive the tracer, then undergo PET/CT followed by planned laparoscopy, with surgical findings and tissue analysis used for comparison. An optional NeuroEXPLORER high-resolution PET/CT may be performed after the same tracer dose to see if smaller lesions can be identified. The study aims to determine how well the tracer identifies lesions seen during surgery and whether it reveals additional lesions beyond ultrasound or MRI.

Why it matters

Potential benefit: If successful, this imaging approach could improve preoperative detection of endometriosis and help guide surgical planning.

How similar studies have gone: Prior research in oncology and other diseases supports FAPI-based PET imaging; this exact endometriosis application is exploratory and builds on emerging evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Voluntary written informed consent of the participant has been obtained prior to any screening procedures.
* At least 18 years of age at the time of signing the Informed Consent Form (ICF).
* At least one of the following to be eligible for the DE cohort: (i) Clinical suspicion of DE, defined as the presence of deep nodule(s) during vaginal examination determined by a clinician who is an expert in endometriosis. (ii) Diagnostic suspicion of DE, defined as an ultrasound and/or MRI that shows lesions suspicious for DE.
* At least one of the following to be eligible for the SPE cohort: (i) Clinical suspicion of SPE, defined as clinical symptoms suspicious of SPE determined by a clinician who is an expert in endometriosis. These clinical symptoms include dysmenorrhea, deep dyspareunia, dysuria, dyschezia, painful rectal bleeding or haematuria, shoulder tip pain, catamenial pneumothorax, cyclical cough/haemoptysis/chest pain, cyclical scar swelling and pain, fatigue, and infertility. (ii) Diagnostic suspicion of SPE, defined as an ultrasound and/or MRI that shows lesions suspicious for SPE.
* Planned laparoscopy for suspected endometriosis.

Exclusion Criteria:

* For SPE cohort: (i) Ultrasound and/or MRI with lesions suspicious of ovarian endometriosis and/or DE. (ii) Clinical symptoms suspicious of ovarian endometriosis and/or DE, determined by a clinician who is an expert in endometriosis.
* Prior abdominal surgery less than one year ago.
* Female who is pregnant, breastfeeding or is of childbearing potential and not using an adequate, highly effective contraceptive or no usage of contraception when sexually active are not accepted.
* Participant is mentally or legally incapacitated, does not understand the study design or is not willing or capable to undergo all study-specific procedures.
* Any disorder or condition, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol, or may influence the result of the study.
* Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial.
* Participation in an interventional Trial with an investigational medicinal product (IMP) or device when the trial designs are not considered compatible by the study team.
* Participation in a clinical scientific study in the last 12 months with a radiation exposure caused by the experimental procedures greater than 1 mSv.
* Participant has a known hypersensitivity to \[18F\]AlF-FAPI-74 or the used excipients.

Where it's running

  • UZ Leuven
    Leuven, Belgium
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.